# TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct05955391/  
OnCo record `nct05955391` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TGRX-326 in non-small-cell lung cancer and small-cell lung cancer, run by Shenzhen TargetRx Co., Ltd., active and no longer recruiting.

## Summary

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT05955391 by Shenzhen TargetRx Co., Ltd., with 164 participants enrolled, started 2023-01-18 and due to reach its primary completion in 2024-12-29. Interventions recorded: TGRX-326. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05955391
- Phase: 2
- Setting: A Multi-centered, Open-label, Single-arm Phase II Study to Evaluate the Safety and Efficacy of TGRX-326 Monotherapy in Patients of Advanced ALK-positiveNon-Small Cell Lung Cancer Who Failed 2nd-Generation ALK Inhibitor Therapies
- Sponsor: Shenzhen TargetRx Co., Ltd.
- Enrolled: 164

## Sources

- ClinicalTrials.gov NCT05955391: https://clinicaltrials.gov/study/NCT05955391

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [TGRX-326](https://onco.cc/drugs/tgrx-326/)
- companies: [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/)

---
JSON: https://onco.cc/api/v1/entities/nct05955391.json